A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Rhea N. Coler(Infectious Disease Research Institute), Neal Van Hoeven(Sana Biotechnology (United States)), Jim Reed(Infectious Disease Research Institute), Sylvie Bertholet(GlaxoSmithKline (United States)), Vanitha S. Raman(Centers for Disease Control and Prevention), Susan L. Baldwin(Seattle Children's Hospital), Kathy Hancock(Centers for Disease Control and Prevention), Joshua DeVos(Centers for Disease Control and Prevention), Malcolm S. Duthie(Health Decision Technologies (United States)), Christopher H. Clegg(TRIA Bioscience (United States)), Steven G. Reed(Infectious Disease Research Institute), Jacqueline M. Katz(National Center for Immunization and Respiratory Diseases), Xiuhua Lu(Centers for Disease Control and Prevention), Narek Shaverdian(University of Wisconsin–Madison), Thomas S. Vedvick(Infectious Disease Research Institute)
Cited by 146
Related Papers
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
|Nature Medicine|2007|1.4k
Key roles of adjuvants in modern vaccines
|Nature Medicine|2013|1.4k
A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission
|Science|2007|582
Avian Influenza (H5N1) Viruses Isolated from Humans in Asia in 2004 Exhibit Increased Virulence in Mammals
|Journal of Virology|2005|460
Lack of transmission of H5N1 avian–human reassortant influenza viruses in a ferret model
|Proceedings of the National Academy of Sciences|2006|347